Open access
Sep 2026
PD-L1 Expression as a Predictor of Response to Neoadjuvant Immunotherapy in Triple-Negative Breast Cancer
Background: Immune checkpoint blockade has changed the treatment of high-risk early-stage triple-negative breast cancer (TNBC), yet the clinical role of programmed death-ligand 1 (PD-L1) expression in the neoadjuvant setting remains unsettled. PD-L1 may identify an immune-enriched tumor microenvironment and therefore c...
Naznin Nahida, Dhruba Tasnim, Israt Jahan Mukta et al.
· Journal of Evidence-Based Me... · 0 citations